Roche's 2024 R&D Day Highlights: In-Licensing Two CDK4 Inhibitors and a Wnt Agonist

Oct 01, 2024 00:08 CST Updated 00:08

Regor Therapeutics

Pharmaceutical R&D Developer

Follow the official account and reply "2024 Roche R&D Day"Get 169-page PPT"

Yesterday, Regor Therapeutics announced an $850 million upfront asset deal with Roche's Genentech. The deal involves CDK inhibitor assets developed by Regor Therapeutics. Due to incomplete disclosure of information, after reviewing the 169-page PPT from Roche’s 2024 R&D Day, it was found that the transaction includes two pipelines: RGT-419B (a CDK4/2 inhibitor) and a CDK4 inhibitor.RGT-587 (Phase I-Ready), Does Not Contain CDK2 InhibitorQR-6401。（$850 Million Upfront Payment! Regor's Three CDK Inhibitors?）

Roche's pharmaceutical business plans to launch 20 innovative drugs through internal R&D and BD cooperation and acquisitions from 2020 to 2029.

Follow the official account below to explore the world with you!